EUVIMEDEUVIMED entdecken
Crossref

Ubiquitin-Specific Protease 52 as a Prognostic Biomarker Correlates with Tumor Microenvironment and Therapy Response in Colorectal Cancer

Jingkai Zhou, Haihang Nie, Xiaoqiang Yang, Fan Wang, Panpan Yu, Yali Yu, Yumei Ning, Jun Lai, Haizhou Wang, Qiu Zhao, Fei Xu

Oncology · 2024

DOI: 10.1159/000540441 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Jingkai Zhou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Tumor Microenvironment, Biomarkers, Tumor, Ubiquitin-Specific Proteases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

As the primary members of the deubiquitinase family, ubiquitin-specific proteases can regulate the efficacy of immunotherapy and mediate immune evasion. However, further research is needed to explore the influence of USP52 on the prognosis of colorectal cancer (CRC), the tumor immune microenvironment, and therapeutic response.

Methods

The differential expression of USP52 between CRC and normal tissues was analyzed using multiple public databases. The relationship between USP52 with the prognosis and clinicopathological characteristics of CRC patients was evaluated, and a nomogram was constructed to predict patient survival based on USP52 expression. Subsequently, gene set variation analysis (GSVA) was used to explore the potential biological functions of USP52 in CRC. The impact of USP52 on the tumor microenvironment (TME) was estimated. Moreover, the effect of USP52 on the response to immunotherapy and chemotherapeutic drugs in CRC was investigated. Finally, the correlation between tumor mutation burden (TMB)/microsatellite instability (MSI) status and USP52 was explored.

Results

The expression of USP52 was markedly upregulated in CRC, correlating with a poor prognosis in patients. GSVA uncovered a strong association between high USP52 and immune suppression. Furthermore, high USP52 was found to be correlated with a non-inflamed TME, resulting in reduced immune cell infiltration levels. Additionally, it was observed that patients with high USP52 exhibited low sensitivity to both immunotherapy and chemotherapeutic drugs. Lastly, high USP52 was negatively associated with high TMB and MSI.

Conclusion

This study revealed the significance of USP52 in TME, efficacy of therapy, and clinical prognosis in CRC, offering novel insights for the therapeutic advancements in CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsTumor MicroenvironmentBiomarkers, TumorUbiquitin-Specific ProteasesHumansPrognosisMaleFemaleGene Expression Regulation, NeoplasticMicrosatellite InstabilityImmunotherapyMutation

Stichwörter der Autor:innen

Colorectal cancerImmunotherapyPrognosisTumor microenvironmentUSP52

Substanzen

Biomarkers, TumorUbiquitin-Specific Proteases

Autor:innen und Institutionen

  • Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Hubei Provincial Clinical Research Center for Intestinal and Colorectal Diseases, Wuhan, China.
  • Hubei Key Laboratory of Intestinal and Colorectal Diseases, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Department of Gastroenterology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, China.
  • Department of Medical Cosmetology, Xianning Central Hospital, The First Affiliated Hospital of Hubei University of Science and Technology, Xianning, China.
  • The Infirmary of Hangzhou Power Supply Company of State Grid, Zhejiang Electric Power Co., Ltd., Hangzhou, China.

Zitieren

APA

Zhou, J., Nie, H., Yang, X., Wang, F., Yu, P., Yu, Y., Ning, Y., Lai, J., Wang, H., Zhao, Q., & Xu, F. (2024). Ubiquitin-Specific Protease 52 as a Prognostic Biomarker Correlates with Tumor Microenvironment and Therapy Response in Colorectal Cancer. Oncology. https://doi.org/10.1159/000540441

Vancouver

Zhou J, Nie H, Yang X, Wang F, Yu P, Yu Y, et al. Ubiquitin-Specific Protease 52 as a Prognostic Biomarker Correlates with Tumor Microenvironment and Therapy Response in Colorectal Cancer. Oncology. 2024. doi:10.1159/000540441

BibTeX
@article{Zhou2024,
  author = {Zhou, Jingkai and Nie, Haihang and Yang, Xiaoqiang and Wang, Fan and Yu, Panpan and Yu, Yali and Ning, Yumei and Lai, Jun and Wang, Haizhou and Zhao, Qiu and Xu, Fei},
  title = {Ubiquitin-Specific Protease 52 as a Prognostic Biomarker Correlates with Tumor Microenvironment and Therapy Response in Colorectal Cancer},
  journal = {Oncology},
  year = {2024},
  doi = {10.1159/000540441}
}
Kostenlos starten →